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                                            INTRODUCTION 
Tablet1 is defined as a solid pharmaceutical dosage form containing drug 
substance with or without suitable diluents and prepared by either compression or 
molding methods. They have been widely used since the later part of the 19th century and 
their popularity still continues. Tablets remain poplar as a dosage from because of the 
advantages afforded both to the manufacture (e.g. simplicity and economy of the 
preparation, stability and convenience in packing, shipping and dispensing) and the 
patient (e.g.accuaracy of dosage, compactness, portability of taste and ease of 
administration. 
 Although the basic medicinal approach for their manufacture has remained the 
same tablet technology has undergone great improvement. Feecets are being made 
continually to understand more clearly the physical characteristics of powder compaction 
and the factors affecting the availability of the drug substance from the dosage form after 
oral administration. There has been a continued interest to improve the tableting 
equipment by increasing the production speed and uniformity of the compressed tablets. 
 Although tablets frequently are discoid in shape they may also be round oval 
oblong cylindrical or triangular. They may differ greatly in size and weight depending on 
the amount of the dug substance resent and the intended method of administration. They 
are divided into two general classes by whether they are made by compression or 
molding, compressed tablets usually are prepared by large scale production methods 
while molded tablets generally involve small scale operation. 
 Tablet formulation and design may be described as the process where by the 
formulator ensures that the current amount of the drug in the right form is delivered at or 
over the proper time rate and in the desired location. While having its chemical integrity 
protected to that point. Most recently, neq concepts and federal regulations being made 
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on bioavailability and bioequivalence and on validation are impacting on tablet 
formulation design and manufacture. 
ADVANTAGE OF TABLETS 
 They are solid unit dosage forms and they offer greatest capabilities of all oral 
dosage forms for the greatest dosage precision and the least content variability. 
 Their cost is lowest of all the dosage forms. 
 They are the lightest and most compact of all the dosage forms. 
 They are in general the easiest and cheapest to package and ship of all oral dosage 
forms. 
 They may provide the greatest ease of swallowing with the least tendency for 
“hang –up” above the stomach especially when coated, provided that tablet 
disintegration is not excessively rapid. 
 They lend themselves to certain special release profile riducts such as enteric or 
delayed release products. 
 They are better suited to large scale production than the other unit oral forms. 
 They have the best combined properties of chemical mechanical and 
microbiologucal stability of all the oral forms. 
 
DISADVANTAGE OF TABLETS 
 Some drugs resist compression into dense particles, owing to their amorphous 
nature or flocculent, low density character. 
 Drugs with poor wetting slow dissolution properties intermediate to large dosages 
high optimum absorption in the GIT, or any combination of these features may be 
difficult or impossible to formulate and manufacture as a tablet. 
 Bitter tasting drugs with an objectionable odor or drugs that are sensitive to 
oxygen or atmospheric moisture may require encapsulation or entrapment prior to 
compression. 
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TYPES OF TABLETS 
1. Compressed tablets (CT) 
2. Multiple compressed tablets 
3. Layered tablets 
4. Compression coated tablets 
5. Repeat action tablets 
6. Delayed action and enteric coated tablets 
7. Sugar coated tablets 
8. Chewable tablets 
9. Buccal tablets 
10. Sublingual tablets 
11. Troches and Lozenges 
12. Dental cones 
13. Implantation tablets 
14. Vaginal tablets  
15. Effervescent tablets 
16. Dispensing tablets 
17. Hypodermic tablets. 
 
TABLET PROCESSING 
 Pharmaceutical products are process all over the world using the direct 
compression, wet granulation or dry granulation methods. . Method2 is chosen depending 
on the ingredients individual characteristics like flow property, compressibility, etc 
choosing a method requires thorough investigation of each ingredient in the formula, the 
combination of ingredients and how they work with each other. Then the proper 
granulation process cab be applied. 
Direct Compression 
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Direct compression name implies compressing tablets directly form powdered materials 
without modifying the physical nature of the materials itself. Direct compression is 
generally done for the crystalline materials having good physical properties required for  
formation of good physical properties required for formation of good tablets. Main 
advantage of direct compression like wet granulation. 
TYPES OF GRANULATION 
1.Wet Granulation  
 The most widely used and the most general method or tablet preparation is by wet 
granulation method. Wet granulation forms the granules by binding the powders together 
with an adhesion instead of by compaction. The wet granulation technique is done by 
adding a solute, suspension or slurry containing binder. This can be aqueous or non 
aqueous which is added to the dry mix powder. In general, the mass should be moist 
rather than wet or paste merely. The surface tension forces and capiliary pressure are 
primarily responsible for intital granules formation. The main disadvantage is that it 
requires many steps in the process, which is time consuming. 
2.Dry Granulation  
 The dry granulation process is used to form granules without using a liquid 
solution. This type of process is recommended for products which are sensitive to 
moisture and heat. Forming granules without moisture requires compacting and 
densifying the powders. Dry granulation can be done on a tablet press using slugging 
tooling. On large scale roller compactor commonly referred to as a chilsonator is used. 
The compacted mass is called slug and the process in known as slugging. The slugs are 
then screened or milled to produce a granular form of tablet materials, which have good 
flow properties than the original mixture. The main advantage of dry granulation is that it 
requires less equipment and eliminates the addition of moisture and the application of 
heat as found in wet massing and drying steps of the wet granulation method. 
Enteric coatings  
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 Enteric coating are those which remain intact in the stomach but will dissolve and 
release the contents once is reaches the small intestine. Their prime intension is to delay 
the release or drugs which are inactivated by the stomach contents or may cause nausea 
or bleeding by irritation of gastric mucosa. 
 Cracking3 of the film either during application or on storage will result in a loss of 
enteric properties. Therefore consideration must  be given to the mechanical properties of 
the applied film. Cracking problems can be effectively overcome by plasticization. 
Plasticizer can also be used to reduce the permeability of the polymer film to water vapor. 
The choice of suitable plastizer is restricted to non water soluble material because these 
are likely to be most effective. 
 An evaluation in made of the solubility parameters of species together with an 
assessment of the intrinsic viscosity of dilute solutions of the polymer on the plasticzers. 
This determines the maximum interaction between polymer and plasticizer and indicates 
which plasticizer is likely to be most effective. 
 A general rule to follow is to use 1 part plasticizer to 10 parts polymer  one should 
also consider viscosity of the plasticizer its influence on the final coating solution its 
effect on film permeability tackiness flexibility solubility and taste and its toxicity 
compatibility with other coating solution components and stability of the film and the 
final coated product. 
Important reasons for enteric Coating are as follows 
 To protect acid liable drugs form the gastric fluid 
 To protect gastric distress or nausea due to irritation form drug  
 To deliver drugs intended for local action in the intestines  
 To deliver drug that are optimally absorbed in the small intestine to their primary 
absorption site in their most concentrated form. 
 To provide a delayed release component to repeat actions 
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 Protect the drugs from harmful effect of the gastric contents: some if the drugs are 
prone to be hydrolyzed in acid media (E.G. Esomeprazole, Omeprazole, 
Pantaprazole) 
Ideal Enteric Coating materials should have the following properties: 
 Resistance to gastric fluids  
 Ready susceptibility to or permeability to intestinal fluids 
 Compatibility with most coating solution components and the drug substrates 
 The film should not change on aging  
 Formation of continuous film 
 Non- toxicity 
 Low cost  
 Ease of application. 
ENTERIC COATING MATERIALS: 
Enteric coatings work because they are selectively insoluble substances they won’t 
dissolve in the acidic juices of the stomach, but they will when they reach the higher pH 
of the small intestine. 
Most enteric coatings won’t dissolve in solutions with a pH lower than 5.5 commonly 
used enteric coating may be made form: 
 Methacrylic acid copolymer  
 Cellulose acetate (and its succinate and phthalate version) 
 Polymethacrylic acid /acrylic acid copolymer 
 Hydroxypropyl methyl cellulose phthalate 
 Cellulose acetate tetrahydrophtalate 
 Acrylic resin 
 Shellac 
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The earliest enteric coatings utilized formalized gelatin, this was unreliable because of 
the polymerization of gelatin could not be accurately controlled. Another was shellac 
disadvantage was polymerization with time resulting in poor dissolution of the coating.  
The most extensively used polymer are CAP, PVAP, the most recently used polymer are 
HPMCP, Methacrylic acid copolymer. 
Cellulose Acetate Phthalate (CAP): 
Effective enteric coating it only dissolves above pH 6 and may delay drug release longer 
than desired. It is permeable to moisture and simulated gastric fluid in comparison with 
other enteric polymers and it is susceptible to hydrolytic breakdown on storage. 
Poly Vinyl Acetate Phthalate (PVAP) 
Less permeable to moisture and simulated gastric juice it is more stable to 
hydrolysis on storage enteric dosage forms coated with PVAP disintegrates at pH5. 
Hydroxy Propyl Methyl Cellulose Phthalate (HPMCP): 
 It is available in two grades HP50 and HP55. 
 HP55 Solutions are more viscous than HP50. 
 HP50 disintegrates at pH5 and HP 55 disintegrates at pH5.5 
It has stability similar to that of PVAP and dissolves in the same pH range. The 
advantage is that it does not require plasticizer. 
Methacrylic acid copolymer: 
Two grades are available A and B which differs in the ration of free carboxyl to ester 
groups therefore. 
Type A has a ration of 1:1 and disintegrates at pH6 
Type B has a ration of 1:2 and disintegrates at pH7. 
Available under the trade names Eufragit L and S correspond to NF types A &B. 
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COATING EQUIPMENT: 
Most of the coating processes use one of three general types of equipment  
1. The standard coating pan  
2. The perforated coating pan 
3. The Fluidized bed coater. 
CONVENTIONAL PAN SYSTEM: 
 The standard4 coating pan system consists of a circular metal pan mounted some 
what angularly on a stand the pan is rotated on its horizontal axis by a motor the hor air is 
directed into the pa and onto the bed surface, and is exhausted by means of ducts 
positioned through the front of the pan. Coating solutions are applied by spraying the 
materials on the bed surface. 
THE PERFORATED COATING PAN: 
Neocota is an automatic coating system for tablets and pellets. Neocota is a 
completely updated automatic coating system having a batch capacity of 500 got 1 kg. 
this model efficiently carries out the following operations. Aqueous film coating of 
tablets /pellets: Non –aqueous organic solvent based film coating of tablets/ pellets; and 
enteric film coating of tablets/ pellets.  
The basic units of the system are coating pan has perforations along its cylindrical 
portion. It is driven by a variable speed drive with a flame proof motor, supply of hot air 
and exhaust of drying air are arranged to facilitate the coating system through stainless 
steel plenums positioned on both sides of the perforated coating pan. The pan is enclosed 
in a cylindrical airtight housing provided with a suitable door and front glass window. 
This housing of pan with drive is a stainless steel basinet accommodating the gearbox, 
AC variable drive power panel hot air unit ex- haust unit and an air fitter. 
Liquid spray system is complete with stainless steel liquid storage vessel, variable flow 
rate liquid dosing pump automatic spray gun and inter connecting flexible hoses. 
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The Fluidized bed coater: 
The fluid Bed technology offers a very efficient coating technique. 
The major advantage of the fluid Bed systems is that it is as per GMP standards it is a 
closed system. 
The second advantage of the fluid Bed Systems is that not only coating but granulation 
and pellet formation is also possible in the same machine. 
Fluidized bed coating is a process that takes place inside a fluidized bed whereby a coat is 
introduced to cover the intended objective in order to protect it or modify its behavior 
particulate coating is a form of fluidized bed coating involving the coating of solid. 
 Particles by spraying with a solution of the coating material. The fluidizing gas is also 
use to dry the deposited solution to form a coat on the surface of the particle.  
There is considerable diversity in methods of using fluidized bed technology. For e.g 
liquids can be applied to fluidized particles in a variety of ways, including top bottom and 
tangential spraying. For a given product each method can offer markedly different 
finished product characteristics. 
Fluidized beds are used for coating because of their high energy and mass transfer 
fluidized beds for film coating can be divided into there groups. 
 Top Spray 
 Tangential Spray 
 Bottom Spray equipment  
Top Spry  
The expansion chamber is lengthened to allow powder to remain fluidized linger and to 
move with a higher velocity so that agglomerations is minimized. The expansion 
chamber is conically shaped to allow uniform deceleration of air stream. 
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The filter housing is larger and designed to shake the fines back into the bed interrupting 
fluidization this reduces agglomeration tendencies. 
The nozzle is positioned low in the expansion chamber so that coating materials impinge 
on the fluidized particle a short distance form the nozzle : this reduces droplet spray 
drying and provides for longer subsequent drying of the coated particles. 
The top spray coater has been used to apply aqueous and organic solvent  based film 
coating controlled release coatings. 
 
Bottom spray coating 10 (Wurster process, Make- GLATT) 
  The wurster machine employs a cylindrical product container with a perforated plate. 
Inside the container is a second cylinder (coating partition) with is raised slightly above 
the perforated plate, centered in the plate below this partition is a spray nozzle  used to 
dispense the coating solution. The perforated plated is designed with large holes in the 
area under the coating partition and smaller holes in the remainder of the plate, except for 
one ring of large holes at the perimeter. The design allows the substrate particles to be 
pneumatically transported upward through the coating partition and downward outside 
this partition. Material passing through coating partition receives a layer of coating 
materials dries in the expansion chamber and falls back in a semi fluidized state. 
Materials circulates rapidly in this fashion and receives layer of coating materials dries in 
the expansion chamber and falls back in a semi fluidized state materials circulates repaid 
in this fashion and receives a layer of coating on each pass through the coating partition. 
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The ring of large holes on the periphery of perforated plate prevents the accumulation of 
materials at the container wall. It has been for coating small particles pellets and tablets. 
 
FLUID END COATING 
 Particles smaller than approx.2mm should be coated in fluid equipments because 
with decreasing particle diameter the specific surface area of a substrate increase 
dramatically thus the required coating weight gain is much higher than tablet coating 
processes. In order to achieve acceptable process times the high efficiency of fluid bed 
compared to pan coating equipment shows clear advantages in particles coating 
processes. 
SHAPE- in order to achieve good flow properties spherical particles with smooth 
surfaces are preferred, while needle shaped particles show poor flow properties and tend 
to form lumps. Another advantage of the latter is the increased risk of breakage during 
the coating process creating un coated spaces and leading to an increased coating weight 
gain besides crystals and pellets granules can be used as substrates as a disadvantages we 
may have uneven surfaces and often increased abrasion compared to the shapes 
 
 
Department of Pharmaceutics  
 
19
mentioned first which can also lead to increased surface areas which requires higher 
amounts of coating. 
SIZE –Usual particle sizes are in arrange of 0.2-1.2 mm. smaller particles may have 
problematic flow properties in higher scale and may tend to break if the length /diameter 
ratio is 2. Smaller particle size are required if particles are administered form sachets or 
incorporated into chewable tablets in order to avoid damage by chewing the coated 
particles should have a maximum size of 0.4mm smaller end products may given a better 
mouth felling but increasing specific surface areas requires higher coating amounts. 
TOP/BOTTOM/TANGENTAL SPRAY 
The top spray method is known and used for particle coating and granulation processes. 
Compared to other fluid bed coating technologies the top spray method is susceptible for 
porous film structure especially if organic coating formulations are processed. Bottom 
spraying (wurster process ) is the usual method in particle compared to the top spray 
method and the required polymer weight gain for a certain functions usually lower to 
some extent. A disadvantage is that in case of nozzle can blockage during the coating 
process, the product must be discharged before the nozzle can be cleaned. Tangential 
spraying system which is commonly fitted with a rotating bottom plate, can achieve film 
quantities nearly as good as bottom spraying system. The rotation of the plate nicely 
supports product movement so that the required air amount is mainly used for drying 
process and only to a smaller degree for the product movement. 
NOZZLES FOR THE PARTICLE COATING 
Common spray gun are air borne with a round spray pattern. Some equipment is 
fitted with a double air supply which is used for common atomizing air and extra 
microclimate air, which surrounds the spray pattern preventing over wetting of the 
products and reducing spray drying effects. 
PUMP SYSTEM. 
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Peristaltic pumps fitted with silicon tubing are standard. Tubing cab be selected in 
a wide range of internal diameters in order to keep the flow speed high and hence to 
prevent sedimentation therefore the use  of tubing with small internal diameters 
recommended alternative pump systems include gear pump and piston pump  
ROATING DISK GRANULATION 
Granulation techniques utilizing centrifugal fluidizing drive have been studied 
only recently. These techniques have been extended to coating operations and combined 
with an expansion chamber to form the rotation disk granulator and coater fluid bed 
device. The basic design employs a rotating disk in the product container. 
The disk can be moved up or down to create a variable slit opening between the 
outer perimeter of the disk and the sidewall of the container. Air is drawn into the product 
container through the slit under negative pressure. This fluidizes the materials along the 
circumferential surface of the product container. At the same time the disk rotates at 
varying speeds and moves the products by the centrifugal force to the outer portions 
where it is lifted by the fluidizing air stream into the expansion chamber. As the material 
decelerates, it descends to the center of the disk and repeats the same sequence. 
The fluidization pattern is often described as a spiraling helix or rope like pattern around 
the inside of the rotor chamber. 
Spray nozzles can be immersed in the bed of fluidized materials and spray applied in 
tangential fashion with respect to the particle flow. 
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LITERATURE REVIEW 
 
1. Manish Maheswari et al5 (2006) The developed Tetra cycline Serratiopeptidase 
contain periodontal gel by reducing polymer concentration and to obtain 
reasonable viscosity at lower concentration by addition of viscosity. 
2. TH All Khateeb et al6 (2007) The aim of the study was to investigate the ability 
of Serratiopeptidase  to reduce post operative swelling , pain after 3rd  molar 
surgery  
3. Deependra Singha et al7 Serratiopeptidase loaded poly (D,L  lactic-co-glycolic 
acid) Microspheres were prepared using the modified double emulsion method the 
effect of polymer concentration and external aqeous phase volume on microsphere 
size  and entrapment efficient was studied by 32 full factorial experiment . 
4. Sandhya KV et al8 (2007) The developed liposomal formulation of 
Serratiopeptidase  on caoco-2 cell permeability and oral bio availability liposomes  
Serratiopeptidase was formulated by standard lipid film hydration method with 
drug in hydration medium  
5. Rajvaidya et al (2007)9 The present study aimed to prepare and characterize 
serratiopeptidase bearing multivesicular liposomes for sustained delivery of 
serratiopeptidase. Multivesicular liposomes (MVLs) bearing serratiopeptidase 
were prepared using the double emulsification technique using amphipathic lipid, 
cholesterol, neutral oil and negatively charged lipid and characterized for their 
shape, size, drug entrapment and in vitro drug release. In vivo performance of 
multivesicular liposomes bearing serratiopeptidase was evaluated by assessing 
anti-inflammatory activity using the carrageenan-induced rat paw edema volume 
method and the cotton pellet granuloma method. The results thus obtained were 
compared with those of conventional drug solution and conventional liposomes 
containing serratiopeptidase in equal amounts. 
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6. Sumit Chakraborty et al 10(2009) Pantoprazole 5-(difluoromethoxy)- 2-[(3,4- 
imethoxypyridin-2-yl) methylsulfinyl]- 3H-benzoimidazole is proton pump 
inhibitor belongs to group of benzimidazole . This compound inhabits gastric acid 
formation and there by it is very efficient for the treatment of gastric and 
duodenum ulcers. In aqueous media more acidicthan pH 4 it suffers a practically 
complete decomposition within a period shorter than 10 minutes. Even in solid 
state it is sensitive to heat, humidity, light and especially to substances containing 
an acidic group. Pantoprazole which have an irritant effect on the stomach can be 
coated with a substance that will only dissolve in the small intestine. For such 
types of drugs, enteric coating added to the formulation tends to avoid the 
stomach's acidic exposure, delivering them instead to a basic pH environment 
(intestines pH 5.5 and above) where they do not degrade, and give their desired 
action. 
 
7. Murat Tu¨rkog˘lu et al11 (2003) In this study, fluidized-bed manufactured 
enteric-coated omeprazole pellets were compressed into tablets. The stability of 
the pellets and those of compressed tablets were evaluated for remaining 
omeprazole and for degradation products under an accelerated stability 
protocol.the data were analyzed using the artificial neural network (ANN) and 
analysis of variance (ANOVA). It was found that enteric-coatedomeprazole pellets 
could be compressed into quickly disintegrating tablets using microcrystalline 
cellulose granules as the pressureabsorbing matrix. 
 
8. Michael J. Story et al 12(1976) The advantages of encapsulated enteric-coated 
pellets as dosage forms are discussed theoretically and compared to enteric-coated 
tablets. An enteric-coated tablet may take from approximately 0.5 to more than 8 
hr to pass from the stomach to the duodenum. On the other hand, enteric-coated 
pellets are subjected to dispersion in the stomach, but they pass through the pyloric 
sphincter after a mean residence time in the stomach that would not be different 
from that exhibited by a suspension dosage form. The dispersion effect causes a 
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theoretical reduction in peak blood level over that of an enteric-coated tablet of 
equivalent potency while maintaining bioavailability. It is hypothesized that 
enteric-coated pellets will reduce intestinal side effects that may occur with 
enteric-coated tablet preparations. 
9. J. G. HARDY et al13 (1990) In this study  enteric coated formulation of naproxen 
has been evaluated using 8 healthy subjects and identified that small intestinal 
transit of enteric coated formulation before and after the break fast.  
10. Gonzales, Gilbert et al14 (Application Number: 10/154629) (2003) an enteric-
coated caffeine delivery system includes a caffeine-containing core and an enteric 
coating made of methacrylic acid copolymer. The caffeine delivery system may 
also include a sub coating. The caffeine delivery system resists disintegration and 
release of the caffeine at a pH less than 5, but disintegrates rapidly to release the 
caffeine at a pH greater than about 6.  
 
11. Kim, Sang Min et al 15United States Patent Application 20080292696 The 
invention relates to an enteric, sustained-release tablet comprising paroxetine or a 
hydrates or anhydrides of a pharmaceutically acceptable salt thereof as active 
substance, more particularly to a tablet prepared by coating a sustained-release 
tablet core containing paroxetine with an enteric polymer, wherein the interaction 
between the tablet core and the enteric coating layer is minimized to enable 
constant drug release without regard to the residence time of the tablet  in the 
stomach.  
 
12. Raghavan, Vineeth et al16 WIPO Patent Application WO/2004/058228. An 
enteric coated composition of fluoxetine (N-metthyl- (p-trifluoromethylphenoxy)-
3-phenylpropylamine) in the form of coated tablets and pellets providing gastric 
pH resistance but disintegrating rapidly in intestinal. The composition is suitable 
for oral administration comprising a core consisting of the active fluoxetine and/or 
its pharmaceutically acceptable acid addition salts along with one or more 
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pharmaceutically acceptable excipients with a selective seal coat on said core and 
an enteric coat over said seal coated core. A seal coat of polyvinyl alcohol is 
proposed over which an enteric coat of methacrylic acid copolymer is provided. 
The above enteric coated formulations of fluoxetine involve a cheaper, 
commercially available, easier to apply enteric polymer wherein smaller quantities 
of polymer are required to achieve the desired results. It would provide enteric 
coated formulation of fluoxetine requiring smaller quantities of polymer and yet 
achieve the desired characteristics of gastric pH resistant to release and rapidly 
disintegrating release profile in intestine pH.  
 
13. Curatolo, William J. et al 17 United States Patent Application 20080199527 A 
pharmaceutical composition is disclosed which comprises multiparticulates 
wherein said multiparticulates further comprise an azithromycin core and an 
enteric coating disposed upon said azithromycin core.  
14. Kanazawa, Hashime et al18 United States Patent 6326360 The invention is to 
obtain an oral glycyrrhizin preparation not only manufacturable by a simple 
method but also having an excellent property of being absorbed from the digestive 
tract. In the present invention, such oral preparations are made into enteric forms 
wherein glycyrrhizin is admixed with an effervescent agent in combination with 
an absorption enhancer such as a medium-chain fatty acid or a salt thereof. In the 
preparation of the present invention, it is now possible to achieve an excellent 
absorption of glycyrrhizin from the digestive tract by addition of an effervescent 
agent and, moreover, the preparation can be manufactured by a simple, convenient 
method without special steps. 
 
15. Chen, Chih-ming et al 19United States Patent 5830503 A once-a-day diltiazem 
dosage form which comprises: (a) a core element which is a compressed tablet 
which contains a therapeutic dose of diltiazem and an amount of a solubility 
modulating substance that controls the release of said diltiazem in order to provide 
a therapeutic level over a period of about 24 hours; and (b) on the outer surface of 
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the core element, a sufficient amount of an enteric coating that causes the 
diltiazem to release at a rate that permits the use of once-a-day dosing to maintain 
steady state therapeutic levels of diltiazem.  
 
16. Deshmukh, Abhijit Mukund et al,20 United States Patent Application 
20040170688  An industrially advantageous enteric formulation of Fluoxetin 
without the use of hydroxyl propyl methylcellulose acetate succinate and sucrose 
is covered by this invention. The present invention also covers said enteric 
formulations of Fluoxetin in the form of tablets or capsules with an optional 
separating layer. When in the form of capsules, the separating layer is capsule 
shell itself thus reducing processing step of said enteric formulations. The 
formulation of the present invention along with Fluoxetin or its pharmaceutically 
accepted salts, solvates, enantiomers or mixtures thereof including racemic 
mixture is also contemplated to be within the scope of present invention 
 
17. Wendsj, Stig et al,21 WIPO Patent Application WO/1998/040054 An enteric 
coated oral dosage form comprising sodium amoxycillin, wherein the dosage form 
is a single unit tableted dosage form or a multiple unit tableted dosage form is 
claimed. Processes for the manufacture of the dosage forms as well as the 
formulations, use in the treatment of $i(Helicobacter pylori) infections are 
claimed.  
18. Ikemoto, et al 22 Japanese Patent JP2004175768 To provide a method for 
producing a stabilized omeprazole enteric coated tablet by coating a core tablet 
containing the omeplazole with an intermediate coating layer on the surface of the 
core tablet, then coating an enteric coating layer on the intermediate coated layer 
in this order without containing any alkali reactive compound in the core tablet 
and in the intermediate coated layer. 
19. Ullah, Ismat et al,23 WIPO Patent Application WO/2006/055740  Disclosed is an 
enteric coated bead comprising Ixabepilone, a compound having a structure: (A). 
Also disclosed is a capsule comprising a multitude of the enteric coated beads. 
 
 
Department of Pharmaceutics  
 
26
Further, a method of preparing the enteric coated bead and a method of treating 
cancer or other proliferative diseases using the enteric coated bead are disclosed 
20. Sugita, Katsuji et al24 United States Patent Application 20030175350 The  
invention provides enteric coated preparation excellent in absorbability, containing 
thyrotropin-releasing hormone (TRH) or derivatives thereof as a medicinally 
active ingredient 
21. Kelm, Gary Robert  et al 25WIPO Patent Application WO/1998/022096  The 
present invention relates to a pharmaceutical composition in a unit dosage form for 
per oral administration in a human or lower animal, having a gastrointestinal tract 
comprising a small intestine and a colon with a lumen there through having an 
inlet to the colon from the small intestine, comprising: a) a safe and effective 
amount of a therapeutically active agent incorporated into or coated on the surface 
of a dosage form selected from the group consisting of a spherical substrate, an 
elliptical substrate, a hard capsule, or a compressed tablet, with a maximum 
diameter of about 3 mm to about 10 mm; and b) an enteric polymer coating 
material comprising at least one inner coating layer and one outer coating layer; 
wherein the dosage form has a smooth surface free from edges or sharp curves; the 
elliptical substrate and the hard capsule have a ratio of the long to short diameters 
of no greater than about 1.5; the therapeutically active agent is released at a point 
near the inlet to, or within the colon; each of the inner coating layer(s) is an enteric 
polymer that begins to dissolve in an aqueous media at a pH between about 5 to 
about 6.3; and the outer coating layer is an enteric polymer that begins to dissolve 
in an aqueous media at a pH between about 6.8 to about 7.2.  
22. Eiji Fukui et al (May 2000)26 As a new oral drug delivery system for colon 
targeting, enteric coated timed-release press-coated tablets (ETP tablets) were 
developed by coating enteric polymer on timed-release press-coated tablets 
composed of an outer shell of hydroxypropylcellulose and core tablet containing 
diltiazem hydrochloride (DIL) as a model drug. The results of the in vitro 
dissolution tests in JP 1st fluid (pH 1.2) and JP 2nd fluid (pH 6.8) indicated that 
these tablets showed both acid resistance and timed-release. The gastric emptying 
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time and lag time after gastric emptying were evaluated by determining the times 
at which PPA and DIL first appeared in the plasma (TFAPPA and TFADIL, 
respectively). TFAPPA and TFADIL were about 4 and 7 h, respectively. This 
value of TFAPPA indicated that ETP tablets displayed acid resistance in the 
stomach as well as in JP 1st fluid. Subtraction of TFAPPA from TFADIL gave a 
value of about 3 h which agreed well with the lag time determined by in vitro 
dissolution test in JP 2nd fluid. 
 
23. Ann Debunne et al (March 2004)27 the aim of this study was to investigate the 
influence of formulation and compression parameters on the properties of tablets, 
containing enteric-coated pellets, and on the integrity of the enteric polymer of the 
individual pellets after compression. In addition the piroxicam plasma 
concentrations were determined after single and multiple oral administrations of 
powder, pellet and tablet formulations at a dose of 0.3 mg piroxicam/kg 
bodyweight to dogs. Tablets consisted of enteric-coated pellets (containing 2.5% 
(w/w) piroxicam in combination with microcrystalline cellulose and sodium 
carboxymethylcellulose (using Avicel® PH 101 and Avicel® CL 611 in a ratio of 
1–3)), cushioning waxy pellets and 10% Kollidon® CL (as an external 
disintegrator). 
 
24. M. Marvola et al (June 1998)28 the aim of this study was to develop a multiple-
unit, site-specific drug formulation allowing targeting of drug release in the colon. 
Initially, characteristics of matrix pellets containing various enteric polymers as 
binders were tested. An enteric coating was then added to the formulations. 
Ibuprofen and furosemide were used as model drugs. The former is absorbed 
throughout the gastrointestinal tract, the latter only from upper parts. Methacrylate 
copolymers, hydroxypropyl methylcellulose acetate succinates and cellulose 
acetate phthalate were used as enteric polymers. The properties of the products 
were initially tested via dissolution studies at different pHs, then via 
bioavailability studies in healthy volunteers. The main conclusion was that drug 
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release can be targeted on the distal part of the small intestine and the colon by 
preparing film-coated matrix pellets in which enteric polymers dissolving at pHø7 
have been used both as binders in the pellets and as coating material. 
 
25. Ehab A.Hosny et al29 (December 1995) Polycarbophil containing diclofenac 
sodium tablets were formulated using two different size of granules. The granules 
were obtained by evaporation under reduced pressure of polycarbophil particles 
loaded with alcoholic solution of the drug. The in-vitro release of these 
bioadhesive containing tablets was evaluated together with that of Ciba-Geigy 
commercially available enteric coated tablets 'Voltaren' in simulated gastric fluid 
for 2 h followed by another 2 h in simulated intestinal fluid. The Voltaren tablets 
released no drug in simulated gastric fluid but released all their drug contents 
within 1 h in simulated intestinal fluid. The tablets formulated using polycarbophil 
granules of smaller size (0.18-0.313 mm) released about 13% of their drug 
contents in simulated gastric fluid and released the remaining drug in simulated 
intestinal fluid within 0.5 h of dissolution, while tablets formulated with larger 
granules size (0.5-0.8 mm) released 10% of their drug contents in the first medium 
and released the remaining drug within 2 h in the second.  The results also 
indicated the effect of bioadhesive granules size on rate and extent of absorption 
where tablets formulated with smaller granules size showed higher C .... shorter 
Tma~, larger AUC and higher relative bioavailability compared with those tablets 
formulated with larger granules size. 
 
26. L. Diane Bruce et al 30(July 2003) the influence of sub coat application and 
micro-environmental pH on the dissolution properties of enteric coated sodium 
valproate pellets was investigated. The pellets were prepared by solution-layering 
or wet-mass extrusion-spheronization methods. In order to pass the 
USP enteric test, the solution-layered and wet-mass extruded pellets required 35 
and 25% weight gain of Eudragit® L 30D-55, respectively. The application of a 
sub coat of either Methocel®-E5 (HPMC) or Opadry® AMB to the pellets 
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resulted in a delay in sodium valproate release in 0.1N HCl. Further delay in drug 
release was observed when citric acid was present in a HPMC sub coat or when 
added to the core pellet formulation. The amount of drug released from coated 
pellets was a function of the level of citric acid in the pellet core or sub coat and 
subsequent micro-environmental pH of the pellets. 
 
27.  W.Y. Donga et al (September 2006)31 The objective of the study was to prepare 
and evaluate carbamazepine-loaded enteric micro particles produced by a novel 
coacervation method. An aqueous polymeric stabilizer solution was added to an 
organic carbamazepine/Eudragit® L100-55 solution. Water, which is a non-
solvent for the drug and the enteric polymer, caused phase separation and the 
formation of coacervate droplets. These droplets hardened into micro particles 
upon further addition of the aqueous phase. The micro particles were characterized 
with respect to particle size distribution, morphology, encapsulation efficiency, 
yield, physical state and physical stability of the drug, wettability, in vitro release 
and in vivo bioavailability. The drug was in a non-crystalline state in the matrix 
and physically stable for 5 months at room temperature. 
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SCOPE AND OBJECTIVE 
 
The aim and objective of this work is to develop small intestine targeting tablets of 
Serratiopeptidase enteric coated tablets-conventional standard coated technique.The 
present study is to develop a pharmaceutically stable, cost effective and quality improved 
formulation of Serratiopeptidase enteric coated tablets. 
 
OBJECTIVES OF THE STUDY:  
The objectives of the present study are: 
 To formulate Serratiopeptidase encapsulated tablets. 
 To evaluate the hardness, friability and in vitro release of Serratiopeptidase. 
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PLAN OF WORK 
1. Extensive literature survey. 
2. Procurement of Excipients. 
3. Procurement of drug (Serratiopeptidase) 
4. Preformulation Studies 
a. Tapped density 
b. Bulk density 
c. Angle of repose 
d. Car’s index 
5. Formulation of Serratiopeptidase enteric coated tablets. 
6. Evaluation of Serratiopeptidase enteric coated tablets. 
a) Hardness 
b) Friability 
c) Disintegration 
d) In- vitro drug release.  
7. Selection of best formulation on the basis of In-vitro drug release 
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DRUG PROFILE 
Synonym           : Shara Bacilli (serratias.p.e 15)32 
Description       : Serratiopeptidase is an enzyme derived from bacteria belongs to genus             
                             Serratia. Serratiopeptidase is a protolytic or protein digestive enzyme. 
Molecular Weight  :  60k Dalton 
Characteristic           :  Fine dry powder 
Description      : off white light brown 
Solubility             :  Readily soluble in water 
Odour                       : Free of Offensive Odour 
Drug Category         :   Analgesics, Anti-Inflammatory 
Indication                :  Trauma Surgery: In sports injuries, fractures, dislocatiand 
Osteoarthritis etc, Serratiopeptidase reduces inflammation and      
helps in faster healing and repair. 
Optimum PH  : 8.5-9.5 
PH stability   : 5-6 
Optimal temperature: 37 c 
 
Mode of action: Serratiopeptidase is a proteolytic enzyme available for clinical use more 
than a decade. Serratiopeptidase binds to alpha -2-macroglobulin in the blood in the ratio 
of 1:1, which helps to mask its antigenicity but retains its enzymatic activity and is 
slowly, transferred to site of inflammation. Serratiopeptidase hydrolyses bradykinin, 
histamine and serotonin responsible for oedematic status. Serratiopeptidase reduces 
swelling improves microcirculation and expectoration of sputum etc. Thus it can be 
concluded that Serratiopeptidase has anti-inflammatory, anti-oedemic and fibrinolytic 
activity and acts rapidly on localized inflammation.Serratiopeptidase when consumed in 
unprotected form is destroyed by acid ion the stomach. However, enteric coated of tablet 
enable the enzyme to pass through the stomach unchanged and absorb in the intestine.  
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Pharmacological action: Anti-inflammatory and anti-edematous actions: 
Serratiopeptidase causes fibrin and bradykinin hydrolysis, without affecting human 
proteins such as albumin and 
Alpha- or gamma-globulins.    
 
Pharmacodynamics: enzymetherapy with anti-inflammatory, anti-edematous and 
Fluidifying action on the locomotive and respiratory systems. 
 
Pharmacokinetics: Following oral administration to experimental animal, peak plasma 
Concentrations were achieved within less than one hour, the highest concentrations being 
found in the lymph. All of the substance was absorbed by the lymph within 6 hours 
following administration and increased in a dose-dependent fashion.     
 
Dosage: Therapy for adults only: The usual recommended dose is one tablet taken 
By mouth 3 times daily with meals. This dose may be increased according to the 
Severity of the condition.    
Dosage forms   :  Capsule and Tablet. 
Applications: 
Surgery: Serratiopeptidase reduces post operative Edema at injection sites. 
Serratiopeptidase reduces internal tissue edema and inflammation caused at post-
operative handling. Reduction in edema reduces chances of rupture at tissue as well as 
risk of in case of plastic surgery graft rejection. 
Respiratory Medicine: Serratiopeptidase breaks down complex sputum molecules into 
smaller peptidase of lower viscosity, helping in expectorating them more easily. Reduced 
viscosity of secretion helps in better antibiotic penetration to enable control over stubborn 
infections like bronchitis,lungabscess. 
ENT: Serratiopeptidase has Mucolytic activity in sinuses, ear cavities and anti –
inflammatory activity in upper respiratory tract organs help in faster resolution, better 
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antibiotic  bioavailability and fastercurerates. 
Dermatology: Serratiopeptidase is used in acute painful inflamed dermatitis. 
Dentistry: Serratiopeptidase helps in better control over dental infections and 
inflammation. 
Obstetrics & Gynecology: The anti-inflammatory activity of Serratiopeptidase helps in 
resolution of post-partum haematomas, breast engorgements and pregnancy related 
thrombophlebitis. 
Male Genital Infection: Serratiopeptidase restores microcirculation and augments 
antibiotic penetration in these organs which are known to produce poor antibiotic 
availability. 
Storage: In sealed container under cool and dry condition. 
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EXCIPIENTS PROFILE 
Cetyl Alcohol 33,34,35 
Synonyms: Avol; Cachalot; Crodacol C70; Crodacol C90; Crodacol C95; ethal; ethol; 1- 
         hexadecanol; n-hexadecyl alcohol; Rita CA; Tego Alkanol 16. 
Chemical Name: Hexadecan-1-ol 
Empirical Formula: C16H34O 242.44 (for pure material) 
Structural Formula: 
                                        
Functional Category: Coating agent; emulsifying agent; stiffening agent 
Applications in Pharmaceutical Formulation or Technology: 
 Cetyl alcohol is widely used in cosmetics and pharmaceutical formulations such as 
suppositories, modified-release solid dosage forms, emulsions, lotions, creams, 
and ointments. 
 In suppositories cetyl alcohol is used to raise the melting point of the base, and in 
modified-release dosage forms it may be used to form a permeable barrier coating.  
 Cetyl alcohol is also used for its water absorption properties in water-in-oil 
emulsions.  
Description:  Cetyl alcohol occurs as waxy, white flakes, granules, cubes, or castings. It 
has a faint characteristic odor and bland taste. 
 
 
Department of Pharmaceutics  
 
36
Solubility:  Freely soluble in ethanol (95%) and ether, solubility increasing with 
increasing temperature; practically insoluble in water.  
Stability and Storage Conditions 
Cetyl alcohol is stable in the presence of acids, alkalis, light, and air; it does not become 
rancid. It should be stored in a well-closed container in a cool, dry place. 
Diethyl Phthalate 
Synonyms:  DEP; ethyl benzene-1,2-dicarboxylate; ethyl phthalate; Kodaflex DEP; 
phthalic acid diethyl ester. 
Chemical Name: 1,2-Benzenedicarboxylic acid, diethyl ester  
Empirical Formula: C12H14O4 222.24 
Structural Formula:  
                                    
Functional Category: Film-former; plasticizer; solvent. 
Applications in Pharmaceutical Formulation or Technology: 
 Diethyl phthalate is used as a plasticizer for film coatings on tablets, beads, and 
granules at concentrations of 10–30% by weight of polymer. 
 Diethyl phthalate is also used as an alcohol denaturant and as a solvent for 
cellulose acetate in the manufacture of varnishes and dopes. 
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Description:  Diethyl phthalate is a clear, colorless, oily liquid. It is practically odorless, 
or with a very slight aromatic odor and a bitter, disagreeable taste. 
Solubility: Miscible with ethanol (95%), ether, and many other organic solvents 
Practically insoluble in water. 
Stability and Storage Conditions: Diethyl phthalate is stable when stored in a well-
closed container in a cool, dry place. 
Hypromellose Phthalate 
Synonyms:  Cellulose phthalate hydroxypropyl methyl ether; HPMCP; hydroxypropyl 
methylcellulose benzene-1,2-dicarboxylate; 2-hydroxypropyl methylcellulose phthalate; 
methylhydroxypropylcellulose phthalate. 
Chemical Name: Cellulose, hydrogen 1,2-benzenedicarboxylate, 2-hydroxypropyl 
methyl ether 
Structural Formula: 
 
Functional Category: Coating agent. 
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Applications in Pharmaceutical Formulation or Technology: 
 Hypromellose phthalate is widely used in oral pharmaceutical formulations as an 
enteric coating material for tablets or granules. 
 Hypromellose phthalate can be applied to tablet surfaces using a dispersion of the 
micronized hypromellose phthalate powder in an aqueous dispersion of a suitable 
plasticizer such as triacetin, triethyl citrate, or diethyl tartrate along with a wetting 
agent. 
 Hypromellose phthalate may be used alone or in combination with other soluble or 
insoluble binders in the preparation of granules with sustained drug-release 
properties. 
Description:  Hypromellose phthalate occurs as white to slightly off-white, free-flowing 
flakes or as a granular powder. It is odorless or with a slightly acidic odor and has a 
barely detectable taste. 
Solubility: 
Readily soluble in a mixture of acetone and methyl or ethyl alcohol (1 : 1), in a mixture 
of methyl alcohol and dichloromethane (1 : 1), and in aqueous alkali. 
Practically insoluble in water and dehydrated alcohol and very slightly soluble in acetone.  
Isopropyl Alcohol 
Synonyms: Dimethyl carbinol; IPA; isopropanol; petrohol; 2-propanol; sec-propyl 
alcohol. 
Chemical Name: Propan-2-ol 
Empirical Formula: C3H8O 60.1 
Structural Formula: 
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Functional Category: Disinfectant; solvent. 
Applications in Pharmaceutical Formulation or Technology: 
 Isopropyl alcohol (propan-2-ol) is used in cosmetics and pharmaceutical 
formulations primarily as a solvent in topical formulations. 
 Isopropyl alcohol is also used as a solvent both for tablet film-coating and for 
tablet granulation. 
 Isopropyl alcohol has some antimicrobial activity. 
Description: 
Isopropyl alcohol is a clear, colorless, mobile, volatile, flammable liquid with a 
characteristic, spirituous odor resembling that of a mixture of ethanol and acetone; it has 
a slightly bitter taste. 
Solubility:  
 Miscible with benzene, chloroform, ethanol (95%), ether, glycerin, and water.  
 Soluble in acetone;  
 Insoluble in salt solutions.  
Stability and Storage Conditions 
Isopropyl alcohol should be stored in an airtight container in a cool, dry place. 
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Lactose, Anhydrous 
Synonyms:  Anhydrous Lactose NF 60M; Anhydrous Lactose NF Direct Tableting; 
lactosum; lattioso; milk sugar; Pharmatose DCL 21; Pharmatose DCL 22; saccharum 
lactis; Super-Tab Anhydrous. 
Chemical Name: O-β-d-galactopyranosyl-(1→4)-β-d-glucopyranose 
 
Empirical Formula: C12H22O11  
Structural Formula: 
                                                 
Functional Category: Binding agent; directly compressible tableting excipient; 
lyophilization aid; tablet and capsule filler. 
Applications in Pharmaceutical Formulation or Technology: 
Anhydrous lactose is widely used in direct compression tableting applications and as a 
tablet and capsule filler and binder. Anhydrous lactose can be used with moisture-
sensitive drugs due to its low moisture content. 
Description: Lactose occurs as white to off-white crystalline particles or powder. 
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Solubility: Soluble in water; sparingly soluble in ethanol (95%) and ether. 
Methylparaben 
Synonyms: 4-hydroxybenzoic acid methyl ester; methyl p-hydroxybenzoate; Nipagin M 
Chemical Name: Methyl-4-hydroxybenzoate 
Empirical Formula: C8H8O3 
         Structural Formula: 
 
 
 
Functional Category: Antimicrobial preservative. 
Applications in Pharmaceutical Formulation or Technology: 
 Methylparaben is widely used as an antimicrobial preservative in cosmetics, food 
products, and pharmaceutical formulations 
 Owing to the poor solubility of the parabens, paraben salts (particularly the 
sodium salt) are more frequently used in formulations. However, this raises the pH 
of poorly buffered formulations. 
 Methylparaben (0.18%) together with propylparaben (0.02%) has been used for 
the preservation of various parenteral pharmaceutical formulations. 
Description: Methylparaben occurs as colorless crystals or a white crystalline powder. It 
is odorless or almost odorless and has a slight burning taste. 
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Titanium Dioxide 
Synonyms: Anatase titanium dioxide; brookite titanium dioxide. 
Chemical Name: Titanium oxide 
Empirical Formula: TiO2  
Structural Formula: TiO2 
Functional Category: Coating agent; opacifier; pigment. 
Applications in Pharmaceutical Formulation or Technology: 
 Titanium dioxide is widely used in confectionery, cosmetics, and foods, in the 
plastics industry, and in topical and oral pharmaceutical formulations as a white 
pigment. 
 Owing to its high refractive index, titanium dioxide has light-scattering properties 
that may be exploited in its use as a white pigment and opacifier.  
 Titanium dioxide is also used in dermatological preparations and cosmetics, such 
as sunscreens. 
Description: White, amorphous, odorless, and tasteless nonhygroscopic powder.  
Solubility: 
 Practically insoluble in dilute sulfuric acid, hydrochloric acid, nitric acid, organic 
solvents, and water. 
 Soluble in hydrofluoric acid and hot concentrated sulfuric acid.  
 
Magnesium Stearate 
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 Synonyms: Magnesium octadecanoate; octadecanoic acid, magnesium salt; stearic acid, 
magnesium salt. 
Chemical Name: Octadecanoic acid magnesium salt 
Empirical Formula: C36H70MgO4  
Structural Formula: [CH3(CH2)16COO]2Mg 
 Functional Category: Tablet and capsule lubricant. 
Applications in Pharmaceutical Formulation or Technology 
Magnesium stearate is widely used in cosmetics, foods, and pharmaceutical formulations. 
It is primarily used as a lubricant in capsule and tablet manufacture at concentrations 
between 0.25% and 5.0% w/w. It is also used in barrier creams. 
 Description: Magnesium stearate is a very fine, light white, precipitated or milled, 
impalpable powder of low bulk density, having a faint odor of stearic acid and a 
characteristic taste. The powder is greasy to the touch and readily adheres to the skin. 
Typical Properties 
Crystalline forms:  High-purity magnesium stearate has been isolated as a trihydrate, a 
dihydrate, and an anhydrate. 
Density (bulk): 0.159 g/cm3  
Density (tapped): 0.286 g/cm3 
Density (true): 1.092 g/cm3 
Flash point: 250°C 
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Flowability: poorly flowing, cohesive powder. 
Melting range: 
 117–150°C (commercial samples); 
 126–130°C (high purity magnesium stearate). 
Solubility: practically insoluble in ethanol, ethanol (95%), ether and water; slightly 
soluble in warm benzene and warm ethanol (95%). 
Acetone 
Synonyms: Dimethylformaldehyde; dimethyl ketone; β-ketopropane; pyroacetic ether. 
Chemical Name: 2-Propanone 
 Empirical Formula: C3H6O  
 Structural Formula:  
 
Functional Category: Solvent. 
Applications in Pharmaceutical Formulation or Technology: Acetone is used as a 
solvent or cosolvent in topical preparations, and as an aid in wet granulation. It has also 
been used when formulating tablets with water-sensitive active ingredients, or to solvate 
poorly water-soluble binders in a wet granulation process. Acetone has also been used in 
the formulation of microspheres to enhance drug release.Owing to its low boiling point, 
acetone has been used to extract thermolabile substances from crude drugs. 
Description: Acetone is a colorless volatile, flammable, transparent liquid, with a 
sweetish odor and pungent sweetish taste. 
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Typical Properties: 
Boiling point: 56.2°C 
Flash point: –20°C 
Melting point: 94.3°C 
Refractive index: n20D = 1.359 
Solubility: soluble in water; freely soluble in ethanol (95%) 
Vapor pressure: 185 mmHg at 20°C 
Stability and Storage Conditions: Acetone should be stored in a cool, dry, well-
ventilated place out of direct sunlight. 
Propyl paraben sodium  
Chemical Name: sodium propyl p-hydroxybenzoate 
Trade Name: propyl paraben sodium 
Molecular Formula: C10H11O3Na 
MolecularWeight: 202.2 
Physical and Chemical Properties: This chemical is white hygroscopic crystalline 
powder. It is easily dissolved in water and alkaline  
Synonyms: Sodium propyl p-hydroxybenzoate; 4-Hydroxybenzoic acid propyl ester 
sodium salt 
Molecular Structure:    
Molecular Formula:   C10H11NaO3 
Molecular Weight:  202.18 
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MATERIALS 
 
S.NO Materials Use 
1.  Lactose Diluent 
2.  Maize starch Disintegrating agent/ 
Binding agent 
3.  Methyl paraben sodium Preservative 
4.  Propile paraben sodium Preservative 
5.  Magnesium sterate Anti adherent 
6.  HPMC 15 cps Polymer 
7.  HPMC pthalate Polymer 
8.  Propyline glycol Plastecizer 
9.  Isopropile Alcohol Solvent 
10.  Iron red oxide Coloring agent 
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EQUIPMENTS 
 
S. No. Instruments Used in section 
1.  Weighing Balance Store In process 
2.  DM Water plant All processing areas 
3.  Mass mixers Granulation 
4.  Mechanical vibrating shifter Granulation 
5.  Fluid bed drier Granulation 
6.  Multy mill Granulation 
7.  Tablet compression machine Compression 
8.  Coating machine Coating 
9.  Sieves Granulation 
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METHADOLOGY 
STEP 1:DISPENSING AND RECEIPT OF RAW MATERIALS 
1, Dispensing and receipt operation is to be carried as per the sop. 
2. Dispense the materials as per the raw materials requisition and duly 
3. Weigh the raw materials in double poly-linedHDPE container and affix materials issue 
slips with all details 
4. Dispense the purified water in SS vessels 
STEP 2: SIFTING OF MATERIALS 
Sift the following materials using mechanical vibrating sifter in to individual poly-lined 
HDPE DRUMS, tie properly and affix container label with details 
S.NO MATERIALS MESH NO 
1 Lactose 20 
2 Maize Starch 40 
3 Magnesium Stearate 40 
 
STEP3: BINDING AGENT PREPARATION 
1. Dissolve methyl paraben sodium ip and propyl paraben sodium ip in boiling purified                     
water 
2 disperse maize starch ip in cold purified water in a separate SS vessel to form starch 
slurry and filter through 100# 
3. Add above starch slurry to boiling water (stage 1) under continuous stirring 
 
 
Department of Pharmaceutics  
 
49
4. mix thoroughly, weigh and adjust the weight with purified water (if necessary) allow it 
to cool 600c  
STEP4:  MIXING 
1. load the sifted lactose and maize starch in mass mixer slowly so that no spillage of 
material occur and close the lid .switch on the mixer and run for 30 minutes 
STEP5:  GRANULATION (WET MIXING) 
1. Open the lid mixture, add the entire quantity of starch at a time, and the close the lid 
properly. 
2. Switch on the mixture run for 2 min, switch off the mixer wipe the paddles and shaft of 
the mixture to remove the wet mass adhered  
3. switch on the mass mixture and run for 2 min more to form wet granular mass as per 
the requirement  
4. Un load the wet material in plastic tube and mill the wet mass through multi mill fitted 
with 8 mm mesh  
STEP6: DRYING 
 1. Place the bowl of FBD below the discharge chute of the multi mill and collect the wet 
granules in to the bowl of sufficient quantity for drying. 
2. Place the bowl of FBD in operating position set the temperature at 650c and switch on 
the FBD. 
3 dry the materials to the required moisture content1.9 to2.4% 
4 unload the dried material in to poly-lined HDPE containers and label accordingly 
5 the drying again loads wet mass or granules of this batch and repeat the drying 
operation. 
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6 if tray dryer is to be used for drying place the wet granules in trays and keep in tray 
dryer. 
7. Set the temperature at 65oc and switch on the tray dryer and run for5to6 hours or to 
attain required moisture content in granules. 
8 unload the dried granules in poly-lined HDPE container and label accordingly 
STEP 7: SIFTING AND MILLING 
1 sifts the dried materials through20# by operating mechanical vibrating sifter and collect 
in poly bags  
2. Mill the retains (coarse granules) which are left on sieve, through multi mill fitted with 
2mm screen  
3. Resift the milled material through 20# and add to sifted granules 
STEP8 BLENDING 
 1. Load the sifted and milled granules in mass mixer 
2. Add serratiopeptidase to mass mixer and mix for 10 min  
3. To this add the weighed quantities of lubricating material of magnesium stearate and 
maize starch in to the mass mixer  
4. Operate the mass mixer for 5min  
5. Transfer the blended granules in to poly ethylene bags lined containers with proper 
label  
6. Weigh, record and store the granules in the quarantine  
7. Send requisition to QC to collect samples of blend.   
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STEP9: COMPRESSION 
Set the compression machine with 7.0mm size, round and normal concave shape upper 
and lower punches and dies. Load the blended granules in to the hopper and start 
compression. 
Process Flow Chart 
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PREFORMULATION STUDIES 
Preformulation36 activities range from supporting discovery’s identification of new 
active agents to characterizing physical properties necessary for the design of dosage 
form. Critical information provided during preformulation can enhance the rapid and 
successful introduction of new therapeutics entities for humans. Preformulation testing is 
an investigation of physical and chemical properties of a drug substance alone and when 
combined with excipients. It is the first step in the rational development of dosage form. 
Objective 
The overall objective of preformulation testing is to generate information useful in 
developing the formulation which is stable and bioavailability. Further the use of 
preformulation parameters maximizes the chances in formulating an acceptable, safe, 
efficacious and stable product. For any drug substance to formulate into a dosage form, it 
is necessary to study the physicochemical properties of the bulk drug like physical 
appearance, solubility, bulk density, tapped density, compressibility, melting point, 
molecular weight, sieve analysis. 
A.P.I CHARACTERISATION: 
1. Physical appearance   
2. Solubility     
3. Determination of bulk density and tapped density 
4. compressibility index 
5. Loss on drying 
6. Angle of repose 
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1. Physical appearance: A small quantity of serratiopeptidase powder was taken in 
butter paper and viewed in well illuminated place. Finally the colour, odour and texture 
were observed.  
2. Solubility: A semi-quantitative determination of the solubility was made by adding 
solvent in small incremental amount to a test tube containing fixed quantity of solute or 
vice versa. After each addition, the system vigorously shaken and examined visually for 
any undissolved solute particles. The solubility was expressed in terms of ratio of solute 
and solvent.  
3. Determination of bulk density and tapped density: 
It refers to a measurement to describe packing of particles and also used to determine the 
amount of drug that occupies the volume in mg/ml before tapping and after tapping an 
accurately weighed quantity of the powder (W), was carefully poured into the graduated 
cylinder and the volume (Vo) was measured, then the graduated cylinder was closed with 
lid, set into the density determination apparatus. The density apparatus was set for 100 
taps and after that, the volume (Vf) was measured and continued operation till the two 
consecutive readings were equal. The bulk density and tapped density were calculated 
using the following formula:  
 
                                             Bulk density = W / Vo 
                                            Tapped density = W / Vf 
Where, 
                  W = weight of the powder, 
                  VO = initial volume, 
                  VF = final volume 
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4. Loss on drying: This is employed in EP, BP and USP. Although, the loss in weight in 
the samples so tested, principally is due to water, small amount of other volatile materials 
will a contribute to the weight loss. The moisture balance combines both the drying 
process and weight recording, it is suitable where large numbers of samples are handled 
and where a continuous record of loss in weight with time is required. The results were 
given in Table No: 21.( LIMIT:  Not more than 0.5% W/W). 
5.Angle of repose:  
This is the maximum angle possible between the surface pile of powder and horizontal 
plane. The frictional forces in the lose powder can be measured by angle of repose. The 
tangent of angle of repose is equal to the co-efficient friction (µ) between the particles. 
Hence the rougher & more irregular the surface of particles the greater will be angle of 
repose. 
                           
θ = tan-1 h/r 
Where, 
h = height of the pile 
r = radius of the pile 
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Angle of repose 
S. No. Angle of repose (degrees) Powder flow 
1. 25-30 Excellent 
2. 31-35 Good 
3. 36-40 Fair 
4. 41-45 passable 
5. 46-55 Poor 
6. 56-65 Very Poor 
7. >66 Extremely poor 
 
6. Compressibility Index: 
The compressibility index is indirectly related to relative flow rate, cohesiveness and 
particle size of the powder.  The compressibility index of material can be estimated from 
the tapped and bulk density of power.    
%Compressibility index = [(T.D – B.D) / T.D] x 100 
Where T.D and B.D are bulk density and tap density respectively.     
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Compressibility Index 
S.No % Comp. Index Powder flow 
1. <10 Excellent 
2. 11-15 Good 
3. 16-20 Fair  
4. 21-25 passable 
5. 26-31 Poor 
6. 32-37 Very Poor 
7. >38 Extremely poor 
 
7. Moisture Content (Or) Water by Kf: 
Take around 50ml of methanol in titration vessel of Karl Fischer titrator and titrate with 
Karl Fischer reagent to end point. In a dry mortar grind the pellets to fine powder .Weigh 
accurately about 0.5 g of the sample, transfer quickly to the titration vessel, stirr to 
dissolve and titrate with Karl Fischer reagent to end point.         
Calculation: 
                   Moisture content =    V X F X 100 
                                                   Weight of Sample in Mg 
Where, 
   F= factor of Karl Fischer reagent.   
   V= volume in ml of Karl Fischer reagent consumed for sample titration.        
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8. Chemical Evaluation: 
Assay: 
Standard preparation: 
Standard serratiopeptdise 100mg into 50ml volumetric flask. Make up the volume with 
0.1 NaoH. From this solution take 25ml into 50ml volumetric flask and make up the 
volume with 5N Hcl. 
Sample Preparation:  
100mg serratiopeptdise into 50ml volumetric flask and make up the volume with 0.1N 
NaoH. Take 25ml into 50ml volumetric flask and make up the volume with 5N Hcl. 
Procedure:  
Take 10ml sample and standard to 50ml volumetric flask + 5ml 20% NaoH cool on ice 
for 10min + 5ml 5% Na2co3 + 2ml folins reagent(folins reagent dilution 1ml to 10ml 
with water).Measure the obsorbants of both the solutions at 660nm. 
Calculation: 
                        AT            WS        2 100  100 
                 A =  ------ × ------ ×    ------- × ---------- × --------- × P 
                         AS    100          100           WT             2 
AT   = Absorbance of the sample preparation. 
AS   = Absorbance of the standard preparation. 
WS  = Weight of the standard taken in mg 
WT  = Weight of the sample taken in mg   
P     = Purity of the standard 
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EVALUATION OF TABLETS 
To design tablets and later monitor tablet production quality, quantitative evaluation and 
assessment of tablet chemical, physical and bioavailability properties must be made. 
The important parameters in the evaluation of tablets can be divided into physical and 
chemical parameters. 
 Physical parameters 
General appearance: 
The general appearance of tablets its visual identity and over all elegance is essential for 
consumer acceptance. The control of general appearance of tablet involves measurement 
of number of attributes such as tablet size, shape, color presence or absence of odor, taste, 
surface texture and consistency of any identification marks.  
Tablet size and thickness: 
Control of physical dimensions of the tablets such as size and thickness is essential for 
consumer acceptance and tablet-tablet uniformity. The diameter size and punch size of 
tablets depends on the die and punches selected for making the tablets. The thickness of 
tablet is measured by Vernier Calipers scale. The thickness of the tablet related to the 
tablet hardness and can be used an initial control parameter. Tablet thickness should be 
controlled within a ±5%. In addition thickness must be controlled to facilitate packaging. 
Average weight of Tablets: 
Take randomly 20 tablets and weigh accurately 20 tablets and calculate the average 
weight. 
Weight of 20 tablets 
Average weight = --------------------------------- 
.     20 
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Weight variation test: 
It is desirable that all the tablets of a particular batch should be uniform in weight. If any 
weight variation is there, that should fall within the prescribed limits: 
                          ±10% for tablets weighing 130mg or less 
                          ±7.5% for tablets weighing 130mg-324mg 
                          ±5% for tablets weighing more than 324mg 
The test is considered correct if not more than two tablets fall outside this range. If 20 
tablets are taken for the test and not more than 1 tablet fall outside this range if only 10 
tablets are taken for the test. The difference of weight in tablets can lead to variation in 
doses. For carrying out this test 20 tablets at random are taken and weighed. The weights 
of individual tablets are then compared to equal to average weight.    
Friability: 
 This test is performed to evaluate the ability to withstand abrasion in packing, handling 
and transporting. Initial weight of 20 tablets is taken and these are placed in the 
friabilator, rotating at 25rpm for 4min. the difference in the weight is noted and expressed 
as %. It should be preferably between 0.5 to 1.0%. 
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DISSOLUTION: 
 
                    . 
 
Dissolution by UV VISIBLE SPECTROSCOPY:  
Dissolution Parameters: 
Type of apparatus: U.S.P. Type II (paddle) 
Medium: 0.1N HCL for 2Hrs,Phosphate buffer pH  6.8 for 45 min. 
RPM: 100 
Volume of Medium:900mL 
Sampling intervals:10min,20min,30min,45min,60min 
Sampling volume : 10mL 
Method of analysis: UV Spectrometric 
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Wave length:660nm.  
Procedure: 
The in-vitro dissolution study was carried out with the USP dissolution test apparatus.900ml of 
dissolution medium (6.8 phosphate buffer) was taken in covered vessel and the temperature was 
maintain at 37 ± 0.5oC.The speed of the paddle was set at 100rpm.Sampling was done every 
10min interval. For each sample 10ml of dissolution medium was withdrawn and the same 
amount of dissolution medium at 37oC was replaced. The sample withdrawn was filtered with 
what man filter paper and diluted with 6.8 phosphate buffer and then analyzed in the UV-
spectrophotometer. The absorbance was measured at 660nm and percentage drug release was 
calculated. 
 Hardness test:- 
 This is to force required to break a tablet in diametric compression. Hard ness of the 
tablet is determined by Stock’s Monsanto hardness tester which consists of a barrel with a 
compressible spring. The pointer moving along the gauze in the barrel which the tablet 
fractures. Hardness of 5 kg considered as suitable for handing the tablet. 
Disintegration test: 
                  For most tablets the first important step toward solution is break down of 
tablet into smaller particles or granules, a process known as disintegration. This is one of 
the important quality control tests for disintegrating type tablets. Six tablets are tested for 
disintegration time using USP XXII apparatus. Disintegration type sustained release 
tablets are tested for disintegrating time. 
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  RESULTS AND DISCUSSION 
FORMULATION TABLE 
 
 
S.No INGREDIENTS (kgs) F1 F2 F3 F4 F5 F6 
              DUMMY GRANULES 
1. LACTOSE 16.10 16.10 16.10 16.10 16.10 16.10 
2. MAIZE STARCH 4.21 4.21 4.21 4.21 4.21 4.21 
3. METHYL PARABEEN 
SODIUM 
0.03 0.03 0.03 0.03 0.03 0.03 
4. PROPYL PARABEEN 
SODIUM 
0.01 0.01 0.01 0.01 0.01 0.01 
5. PURIFIED WATER(Lit) 5.50 5.50 5.50 5.50 5.50 5.50 
6. SERRATIOPEPTIDASE 2.00 2.00 4.00 6.00 4.00 2.00 
7. MAGNESIUM STEARATE 0.35 0.35 0.35 0.35 0.35 0.35 
           SUB COATING MATERIALS 
8. HPMC 15cps 0.45 0.45 0.45 0.45 0.45 0.45 
9. PROPYLENE GLYCOL 0.12 0.12 0.12 0.12 0.12 0.12 
10. METHYLENE 
CHLORIDE(Lit) 
7.80 7.80 7.80 7.80 7.80 7.80 
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ENTERIC COATING MATERIAL 
 
Coating parameters: 
Pan Rpm: 11-12 
Inlet temperature:50-60oC 
Outlet temperature:45-55oC 
Air pressure:3-4kg/sqcm 
 
S.No INGREDIENTS 
(kgs) 
F1 F2 F3 F4 F5 F6 
11. HPMC PTHALATE 1.83 3.66 1.83 3.66 5.49 5.49 
12. CETYL ALCOHOL 0.12 0.24 0.12 0.24 0.36 0.36 
13. DIETHYL 
PTHALATE 
0.035 0.070 0.035 0.070 0.105 0.105 
14. IRON RED 
OXIDE(gm) 
22.3 22.3 22.3 22.3 22.3 22.3 
15. TITANIUM 
DIOXIDE 
0.035 0.070 0.035 0.070 0.105 0.105 
16. ACETONE(lit) 27.0 27.0 27.0 27.0 27.0 27.0 
17. ISOPROPYL 
(lit)ALCOHOL 
6 6 6 6 6 6 
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Preformulation Characteristics of All Formulations: 
Precompressional parameters: 
The value of precompressional parameters were found to be within the prescribed limits 
and indicated good free flowing property and the results were given in the table.  
S.No Formulations 
Angle of 
Repose 
(º) 
Bulk 
Density 
(gm/ml) 
Tapped 
Density 
(gm/ml) 
Compressibility 
Index 
(%) 
Moisture 
Content 
(%) 
1 F1 25.4 0.55 0.69 20.0 2.1 
2 F2 26.4 0.53 0.67 21.0 2.2 
3 F3 28.2 0.57 0.59 23.0 2.4 
4 F4 28.4 0.55 0.64 19.0 2.2 
5 F5 23.2 0.53 0.62 23.0 2.1 
6 F6 29.6 0.56 0.68 26.0 2.4 
 
 
Chemical Evaluation: 
The assay of all formulations are found to be between 90% - 114%. 
Physical 
parameter 
F1 F2 F3 F4 F5 F6 
Assay% (w/w) 114 99.03 96 95.01 96 92 
 
 
 
Department of Pharmaceutics  
 
65
 
STANDARD GRAPH OF SERRATIOPEPTIDASE: 
Series of dilutions are made from standard working solution with 6.8 pH phosphate 
buffer to get concentrations ranges from 10 -60mcg and the absorbance was measured at 
660nm and the values are listed below. 
Concentration (µg/ml) Absorbance 
10 0.041 
20 0.083 
30 0.124 
40 0.166 
50 0.206 
60 0.245 
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Physical Evaluation: 
Postcompressional parameters: 
The data obtained of postcompressional parameters such as weight variation, thickness, 
friability and hardness, disintegration time were shown in the table. Hardness was found 
to be the range of NLT 3.0kg/cm2  in all the formulations indicating good mechanical 
strength with an ability to withstand physical and mechanical stress conditions were 
handling. In all the formulations the friability values NMT 1.0% giving an indication that 
the tablets formulated are mechanically stable. All the tablets passed weight variation test 
at the percentage weight variation was within the I.P limits. All the tablets passed 
disintegration test NMT 15min as per I.P limits. 
S.NO 
Physical 
Parameters 
F1 F2 F3 F4 F5 F6 
1 
Weight 
Variation (mg) 
0.12 0.11 0.12 0.13 0.13 0.11 
2 
Hardness 
(kg/cm2) 
3.2 3.1 3.4 3.2 3.5 3.2 
3 
Thickness 
(mm) 
3.1 3.3 3.3 3.2 3.5 3.1 
4 Friability (%) 0.25 0.32 0.22 0.45 0.35 0.47 
5 
Disintegration 
Time 
4m20s 6m20s 3m20s 8m32s 10m40s 11m23s 
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SPECIFICATION OF SERRATIOPEPTIDASE 
S. No  Tests  Results  Limits  
1 Description  Off white powder Off white to light 
brown color 
2 Loss on drying 5.88% NMT 7.00w/w 
3 Heavy metal <50ppm  NMT 50ppm 
4 Arsenic  < 5ppm NMT 5ppm 
5 Enzyme activity  2.463u/mg 2, 200u/mg to 
 2, 600u/mg 
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Dissolution Studies of All Formulations: 
By comparing the all formulations F1 formulation showed better percentage drug release. 
S.No Dissolution 
time (min) 
F1 F2 F3 F4 F5 F6 
1 10 32.71 21.73 39.29 37.10 19.54 5.98 
2 20 52.27 33.79 54.93 49.66 25.89 19.00 
3 30 70.79 49.64 76.06 62.88 39.08 29.20 
4 45 89.30 68.49 84.96 81.37 47.09 45.06 
5 60 94.66 78.76 93.93 91.98 57.60 54.98 
6 90 99.94 91.97 95.70 97.38 70.81 67.87 
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COMPARITIVE DISSOLUTION PROFILE OF FORMULATIONS: 
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Formulation 1(6.8 Phosphate buffer) 
S.no Time (min) %drug release 
1 10 32.71 
2 20 52.27 
3 30 70.79 
4 45 89.30 
5 60 94.66 
6 90 99.94 
 
 
 
 
        DISSOLUTION PROFILE FOR SERRATIOPEPTIDASE TABLETS F1 
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Formulation 2 (6.8 Phosphate buffer) 
S.no Time (min) %drug release 
1 10 21.73 
2 20 33.79 
3 30 49.64 
4 45 68.49 
5 60 78.76 
6 90 91.97 
 
 
 
 
DISSOLUTION PROFILE FOR SERRATIOPEPTIDASE TABLETS F2 
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Formulation 3 (6.8 Phosphate buffer) 
S.no Time (min) %drug release 
1 10 39.29 
2 20 54.93 
3 30 76.06 
4 45 84.96 
5 60 93.93 
6 90 95.70 
 
 
 
 
DISSOLUTION PROFILE FOR SERRATIOPEPTIDASE TABLETS F3 
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Formulation 4 (6.8 Phosphate buffer) 
S.no Time (min) %drug release 
1 10 37.10 
2 20 49.66 
3 30 62.88 
4 45 81.37 
5 60 91.98 
6 90 97.38 
 
 
 
 
DISSOLUTION PROFILE FOR SERRATIOPEPTIDASE TABLETS F4 
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Formulation 5 (6.8 Phosphate buffer) 
S.no Time (min) %drug release 
1 10 19.54 
2 20 25.89 
3 30 39.08 
4 45 47.09 
5 60 57.60 
6 90 70.81 
 
 
 
 
DISSOLUTION PROFILE FOR SERRATIOPEPTIDASE TABLETS F5 
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Formulation 6 (6.8 Phosphate buffer) 
S.no Time (min) %drug release 
1 10 5.98 
2 20 19.00 
3 30 29.20 
4 45 45.06 
5 60 54.98 
6 90 67.87 
 
 
 
 
DISSOLUTION PROFILE FOR SERRATIOPEPTIDASE TABLETS F6 
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SUMMARY AND CONCLUSION 
 
   Serratiopeptidase is derived from bacteria belonging to genus Serratia. 
Serratiopeptidase tablets used in the treatment of viral diseases and hepatitis. In this study 
Serratiopeptidase enteric coated tablets were prepared by using HPMC phthalate, HPMC 
15cps (Polymer). 
                Several formulations were made with varying the concentrations of drug 
polymer and enteric coating tablets were done by wet granulation method. They were 
tested for normal quality control tests like disintegration, weight variation, hardness and 
friability. The drug release study is carried out for 2hrs in 0.1N HCl and followed with 
1hr in 6.8 phosphate buffer. 
               The present work of Serratiopeptidase was formulated as delayed release tablet 
which significantly increase the small intestinal absorption and the drug was targeted to 
small intestinal regions. This was achieved by enteric coating of tablets by simple 
standard pan coating method. 
                Serratiopeptidase were formulated using HPMC phthalate as enteric coating 
polymer in different concentrations to optimize delayed drug release profile and to target 
the drug release in the small intestine regions. 
                  The present work was made to develop enteric coated tablets containing 
Serratiopeptidase tablets were made by direct compression method. 
                    While concluding the best formulation among the six F1 formulation shows 
99.94% drug release than the all other formulations.  
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